In a recent study published in npj Parkinson's disease, researchers evaluated the differences in the progression of Parkinson’s disease (PD) between real-world and research populations. There are several challenges to developing disease-modifying therapies for PD; notably, molecular processes driving pathogenesis are poorly understood. Characterization of PD progression can aid in the design of clinical trials and identify sub-populations.